Compare Stocks → Move Your Money Before May 1 (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ALRNNASDAQ:BPTHNASDAQ:CORVNASDAQ:OHRPNASDAQ:ONCS Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALRNAileron Therapeutics$5.01+0.2%$5.41$1.01▼$7.42$85.02M2.2264,743 shs62,741 shsBPTHBio-Path$2.71+2.7%$4.89$2.35▼$44.80$1.84M0.351.11 million shs96,946 shsCORVCorrevio Pharma$0.42$0.41$0.21▼$2.79$27.80M0.085.35 million shsN/AOHRPOHR Pharmaceutical$0.44+4.7%$7.37$1.60▼$6.28$1.25M0.84180,228 shs25,641 shsONCSOncoSec Medical$0.52$0.18▼$20.46$1.26M1.992.22 million shs52.49 million shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALRNAileron Therapeutics+2.64%+1.20%-12.46%+0.40%+255.09%BPTHBio-Path+5.82%-37.26%-34.45%-71.96%-89.20%CORVCorrevio Pharma0.00%0.00%0.00%0.00%0.00%OHRPOHR Pharmaceutical0.00%+0.26%-12.07%-32.12%+220.64%ONCSOncoSec Medical0.00%0.00%0.00%0.00%-68.50%Move Your Money Before May 22 (Ad)The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals. Here's where Dr. David Eifrig says to move your money immediately.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALRNAileron Therapeutics1.5927 of 5 stars3.53.00.00.01.41.70.0BPTHBio-Path2.521 of 5 stars3.55.00.00.02.40.00.6CORVCorrevio PharmaN/AN/AN/AN/AN/AN/AN/AN/AOHRPOHR PharmaceuticalN/AN/AN/AN/AN/AN/AN/AN/AONCSOncoSec MedicalN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALRNAileron Therapeutics3.00Buy$19.00279.24% UpsideBPTHBio-Path3.00Buy$40.001,376.01% UpsideCORVCorrevio PharmaN/AN/AN/AN/AOHRPOHR PharmaceuticalN/AN/AN/AN/AONCSOncoSec MedicalN/AN/AN/AN/ACurrent Analyst RatingsLatest BPTH, ONCS, OHRP, CORV, and ALRN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/18/2024ALRNAileron TherapeuticsLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$9.00 ➝ $19.004/18/2024BPTHBio-PathRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.003/27/2024BPTHBio-PathRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$12.00 ➝ $40.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALRNAileron TherapeuticsN/AN/AN/AN/A$1.41 per shareN/ABPTHBio-PathN/AN/AN/AN/A$0.71 per shareN/ACORVCorrevio Pharma$32.63M0.85N/AN/A($0.02) per share-21.00OHRPOHR PharmaceuticalN/AN/AN/AN/A$3.86 per shareN/AONCSOncoSec MedicalN/AN/AN/AN/A$3.42 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALRNAileron Therapeutics-$15.73M-$3.38N/AN/AN/AN/A-130.32%-39.23%5/13/2024 (Estimated)BPTHBio-Path-$16.08M-$40.80N/AN/AN/AN/A-375.74%-248.63%5/10/2024 (Estimated)CORVCorrevio Pharma-$35.18M-$0.79N/A∞N/A-107.81%-2,128.82%-58.56%N/AOHRPOHR Pharmaceutical-$13.23MN/A0.00∞N/AN/A-75.46%-71.18%N/AONCSOncoSec Medical-$34.18M-$15.29N/AN/AN/AN/A-868.29%-160.61%N/ALatest BPTH, ONCS, OHRP, CORV, and ALRN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/15/2024Q4 2023ALRNAileron TherapeuticsN/A-$1.54-$1.54-$1.54N/AN/A3/8/202412/31/2023BPTHBio-Path-$5.40-$5.40N/AN/AN/AN/A DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALRNAileron TherapeuticsN/AN/AN/AN/AN/ABPTHBio-PathN/AN/AN/AN/AN/ACORVCorrevio PharmaN/AN/AN/AN/AN/AOHRPOHR PharmaceuticalN/AN/AN/AN/AN/AONCSOncoSec MedicalN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALRNAileron TherapeuticsN/A4.174.17BPTHBio-PathN/A1.601.60CORVCorrevio Pharma22.541.070.95OHRPOHR PharmaceuticalN/A3.733.73ONCSOncoSec MedicalN/A0.890.89OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALRNAileron Therapeutics90.89%BPTHBio-Path5.74%CORVCorrevio Pharma7.30%OHRPOHR Pharmaceutical10.70%ONCSOncoSec Medical8.69%Insider OwnershipCompanyInsider OwnershipALRNAileron Therapeutics5.57%BPTHBio-Path3.05%CORVCorrevio PharmaN/AOHRPOHR Pharmaceutical12.50%ONCSOncoSec Medical1.32%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableALRNAileron Therapeutics616.97 million16.03 millionNot OptionableBPTHBio-Path10680,000658,000OptionableCORVCorrevio Pharma13366.19 millionN/AOptionableOHRPOHR Pharmaceutical32.83 millionN/ANot OptionableONCSOncoSec Medical404.55 million4.49 millionNot OptionableBPTH, ONCS, OHRP, CORV, and ALRN HeadlinesSourceHeadlineIs OncoSec Medical Inc (ONCSQ) Stock a Good Investment?aaii.com - June 29 at 2:37 AMONCS - OncoSec Medical Incorporatedfinance.yahoo.com - June 24 at 8:41 AM0 analysts rank ONCS stock as an Overweightknoxdaily.com - June 23 at 6:54 PMWhy Is OncoSec Medical (ONCS) Stock Up 100% Today?markets.businessinsider.com - June 23 at 8:53 AMWhy John Wiley & Sons Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Sessionmsn.com - June 15 at 2:49 PMWhy Is OncoSec Medical (ONCS) Stock Down 48% Today?msn.com - June 15 at 9:48 AMOncoSec Announces Closing of $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rulesfinance.yahoo.com - May 18 at 8:59 PMOncoSec Medical plunges 35% lower on sale of 1.4M shares of common stockmsn.com - May 16 at 4:15 PMOncoSec Announces $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rulesfinance.yahoo.com - May 16 at 4:15 PMOncoSec is encouraged after FDA meeting to discuss proposed neoadjuvant melanoma clinical programfinance.yahoo.com - May 16 at 9:56 AMOncoSec Receives $3.49 Million to Strengthen its Balance Sheet After Selling its Net Operating Loss Tax Benefits Through The New Jersey Economic Development Authority NOL Programfinance.yahoo.com - April 27 at 8:26 AMOncoSec Announces Closing of $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rulesfinance.yahoo.com - April 11 at 5:48 PMWhy OncoSec Medical Shares Are Soaring Todaymsn.com - April 10 at 4:15 PMOncoSec Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rulesfinance.yahoo.com - April 10 at 4:15 PMOncoSec Medical Inc (ONCS) is lower by 6.15% Tuesday In Premarket Tradingbenzinga.com - April 6 at 7:57 PMOncoSec Shares Disappointing Results From Skin Cancer Combo Therapy Trial, Sets Stage For Neoadjuvant Setting Studyfinance.yahoo.com - April 3 at 3:57 PMOncoSec crashes ~60% after TAVO-EP, Keytruda combo fails phase 2 skin cancer trialmsn.com - April 3 at 10:57 AMOncoSec Announces Clinical Data of the KEYNOTE-695 Trial Assessing TAVO™-EP in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Melanoma Refractory to anti-PD-1 Treatmentfinance.yahoo.com - April 3 at 10:57 AMOncoSec Medical Withdraws Planned Offering, Shares Rise Over 50%marketwatch.com - March 1 at 8:56 AMWhy is OncoSec Medical (ONCS) Stock Up 91% Today?msn.com - March 1 at 8:56 AMONCS.OQ - | Stock Price & Latest News | Reutersreuters.com - January 16 at 7:08 PMOncoSec Medical Stock (NASDAQ:ONCS), Quotes and News Summarybenzinga.com - January 5 at 3:51 PMPeering Into OncoSec Medical's Recent Short Interestmsn.com - December 8 at 5:34 PMOncoSec to Present at the RHK Capital Disruptive Growth Conference on December 6, 2022finance.yahoo.com - December 5 at 1:28 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAileron TherapeuticsNASDAQ:ALRNAileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.Bio-PathNASDAQ:BPTHBio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas.Correvio PharmaNASDAQ:CORVCorrevio Pharma Corp., a specialty pharmaceutical company, engages in developing therapeutics worldwide. Its portfolio of marketed brands comprise Aggrastat (tirofiban hydrochloride) for patients with acute coronary syndrome; and Brinavess (vernakalant IV) for the rapid conversion of recent onset atrial fibrillation to sinus rhythm. The company also offers ESMOCARD and ESMOCARD LYO, a short acting beta blocker for the treatment of supraventricular tachycardia and control of the ventricular rate in patients with atrial fibrillation; Trevyent, a development stage drug/device combination product for pulmonary arterial hypertension; Xydalba, a treatment for acute bacterial skin and skin structure infections; and Zevtera/Mabelio, a cephalosporin antibiotic for intravenous administration with rapid bactericidal activity. Correvio Pharma Corp. was incorporated in 2018 and is headquartered in Vancouver, Canada.OHR PharmaceuticalNASDAQ:OHRPOHR Pharmaceutical, Inc. operates as a development stage pharmaceutical company. The company intends to merge with NeuBase Therapeutics, Inc. that focuses on advancing NeuBase's peptide-nucleic acid antisense oligonucleotide technology platform for the development of therapies to address severe and currently untreatable diseases caused by genetic mutations. OHR Pharmaceutical, Inc. is headquartered in New York, New York.OncoSec MedicalNASDAQ:ONCSOncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's product pipeline includes KEYNOTE-695, which is in Phase 2 trial for the treatment of advanced melanoma; TAVO + SARS-CoV-2 spike glycoprotein, which is in Phase 1 clinical trial for the treatment of COVID-19; and TAVO + epacadostat + pembrolizumab, which is in Phase 1 clinical trial for the treatment of squamous cell carcinoma head and neck cancer. Its pipeline also comprises TAVO +nivolumab, which is in Phase 2 clinical trial for the treatment of breast cancer; TAVO + CXCL9 for the treatment of solid tumors; and OMS-100 and OMS-102, which are in Phase 2 clinical trial for the treatment of metastatic melanoma. OncoSec Medical Incorporated has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890; and a research collaboration with Duke University's Center for Applied Therapeutics to evaluate TAVO in combination or sequenced with a HER2-plasmid vaccine. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was incorporated in 2008 and is headquartered in Pennington, New Jersey. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.